Latest news

Thumbnail image for Xtandi successful in prostate cancer Phase III trial

Xtandi successful in prostate cancer Phase III trial

Pfizer and Astellas have unveiled results from the Phase III ARCHES trial in men with metastatic hormone-sensitive prostate cancer (HSPC), showing that Xtandi significantly improved radiographic progression-free survival, paving the way for an application to expand the drug's use.

13th February 2019

Thumbnail image for Bavencio combo gets FDA priority review for kidney cancer

Bavencio combo gets FDA priority review for kidney cancer

The US Food and Drug Administration has accepted for priority review a supplemental Biologics License Application for Merck’s Bavencio (avelumab) in combination with Inlyta (axitinib) for patients with advanced renal cell carcinoma (RCC).

13th February 2019

Thumbnail image for £2m available to revolutionise UK patient care

£2m available to revolutionise UK patient care

The Peter Sowerby Foundation has issued an open call to source a suitable project for up to £2 million of funding as part of the Foundation’s Health Breakthrough funding strand.

13th February 2019

Thumbnail image for New NICE guidelines on antibiotic prescribing for pneumonia

New NICE guidelines on antibiotic prescribing for pneumonia

The National Institute for Health and Care Excellence (NICE) and Public Health England (PHE) have published draft guidance on antimicrobial prescribing for hospital-acquired and community-acquired pneumonia, setting out a strategy designed to optimise antibiotic use and reduce antibiotic resistance.

13th February 2019

Thumbnail image for Yescarta rejected among other SMC decisions

Yescarta rejected among other SMC decisions

Gilead's CAR-T therapy Yescarta has been rejected by the Scottish Medicines Consortium (SMC) for use on NHS Scotland, but Novartis' Kymriah was given a green light.

12th February 2019

Thumbnail image for Takeda’s Adcetris gets EU green light

Takeda’s Adcetris gets EU green light

Takeda has announced that the European Commission has extended the current marketing authorisation of Adcetris to include treatment of adults with previously untreated CD30+ Stage IV Hodgkin lymphoma.

12th February 2019

Previous  --   1 2 3 4 5 6 7 8 9 10   --  Next

Latest jobs

View all

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download